Cadrenal Therapeutics Inc. Common Stock

CVKD | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.12

+$0.03 (+2.75%)

Sep 22, 2026, 2:29 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.75%

(1D)

Rating

Updated: Aug 31, 2026

Fundamentals Weak

Market Sentiment Bearish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $4M

1D Range

1.09 1.12

52W Range

1 14.64

Valuation (TTM)

PE -0.22

PB 0.95

EV/EBITDA -0.13

Valuation (NTM)

Forward PE N/A

Forward PEG 0.01

Price Target $32

Cash Flow

FCF Yield -261.4%

SBC Adj. FCF Yield -305.7%

SBC Impact -17.0%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 10.4% | N/A

FCF 3Y | 5Y -30.9% | N/A

Returns

ROA -206.6%

ROE -406.4%

ROIC -284.8%

Financial Health

Net Cash

$2.39M

Current Ratio 3.73

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent t...

Sector Healthcare

Industry Biotechnology

Employees 5

IPO Date Jan 19, 2023

Website www.cadrenal.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$32

Upside

+2757.14%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞